Gilead Sciences Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $46.88B | $67.95B | $5.34B |
| FY2022 | $41.93B | $63.17B | $5.41B |
| FY2023 | $39.29B | $62.13B | $6.09B |
| FY2024 | $39.67B | $59.00B | $9.99B |
| FY2025 | $36.32B | $59.02B | $7.56B |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $46.88B | $67.95B | $5.34B |
| FY2022 | $41.93B | $63.17B | $5.41B |
| FY2023 | $39.29B | $62.13B | $6.09B |
| FY2024 | $39.67B | $59.00B | $9.99B |
| FY2025 | $36.32B | $59.02B | $7.56B |